MetaVia Inc. (MTVA)Healthcare | Biotechnology | Cambridge, United States | NasdaqCM
1.52 USD
-0.09
(-5.590%) ⇩
(April 23, 2026, 4 p.m.
EDT)
After hours: 1.62 +0.10 (6.862%) ⇧ (April 23, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | April 19, 2026, 1:11 a.m. EDT
Extreme bearish technical divergence triggered by a 1-for-11 reverse split and massive price collapse on extreme negative statistical evidence, confirming the warning target of $1.93. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.224774 |
| AutoETS | 0.249316 |
| AutoTheta | 0.358207 |
| AutoARIMA | 0.531126 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 49% |
| H-stat | 4.51 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.592 |
| Excess Kurtosis | -0.43 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.938 |
| Market Cap | 7,738,222 |
| Beta | 0.35 |
| Website | https://www.metaviatx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.83209985 |
| Address1 | 545 Concord Avenue |
| Address2 | Suite 210 |
| All Time High | 1,424,940.0 |
| All Time Low | 1.17 |
| Ask | 1.57 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 210,890 |
| Average Daily Volume3 Month | 222,064 |
| Average Volume | 222,064 |
| Average Volume10Days | 210,890 |
| Beta | 0.345 |
| Bid | 1.49 |
| Bid Size | 1 |
| Book Value | 2.31 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.52 |
| Current Ratio | 1.925 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.58 |
| Day Low | 1.52 |
| Debt To Equity | 3.938 |
| Display Name | MetaVia |
| Dividend Date | 1,577,750,400 |
| Earnings Timestamp End | 1,755,520,200 |
| Earnings Timestamp Start | 1,755,001,800 |
| Ebitda | -13,689,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.173 |
| Enterprise Value | -2,361,777 |
| Eps Trailing Twelve Months | -7.35 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.4658 |
| Fifty Day Average Change | 0.054199934 |
| Fifty Day Average Change Percent | 0.03697635 |
| Fifty Two Week Change Percent | -83.209984 |
| Fifty Two Week High | 19.03 |
| Fifty Two Week High Change | -17.51 |
| Fifty Two Week High Change Percent | -0.9201261 |
| Fifty Two Week Low | 1.17 |
| Fifty Two Week Low Change | 0.35000002 |
| Fifty Two Week Low Change Percent | 0.29914534 |
| Fifty Two Week Range | 1.17 - 19.03 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,470,403,800,000 |
| Float Shares | 3,338,483 |
| Free Cashflow | -11,278,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 8 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.35 |
| Held Percent Institutions | 0.029830001 |
| Implied Shares Outstanding | 5,090,936 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,764,892,800 |
| Last Split Factor | 1:11 |
| Long Business Summary | MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts. MetaVia Inc. operates as a subsidiary of Dong-A ST Co., Ltd. |
| Long Name | MetaVia Inc. |
| Market | us_market |
| Market Cap | 7,738,222 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_630763379 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -12,973,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 8,196,406 |
| Number Of Analyst Opinions | 3 |
| Open | 1.58 |
| Operating Cashflow | -15,701,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 857 702 9600 |
| Post Market Change | 0.10430002 |
| Post Market Change Percent | 6.8618436 |
| Post Market Price | 1.6243 |
| Post Market Time | 1,776,987,005 |
| Previous Close | 1.61 |
| Price Hint | 4 |
| Price To Book | 0.6580087 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.825 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.09 |
| Regular Market Change Percent | -5.59006 |
| Regular Market Day High | 1.58 |
| Regular Market Day Low | 1.52 |
| Regular Market Day Range | 1.52 - 1.58 |
| Regular Market Open | 1.58 |
| Regular Market Previous Close | 1.61 |
| Regular Market Price | 1.52 |
| Regular Market Time | 1,776,974,401 |
| Regular Market Volume | 105,015 |
| Return On Assets | -0.62575 |
| Return On Equity | -1.95612 |
| Sand P52 Week Change | 0.28653932 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 5,090,936 |
| Shares Percent Shares Out | 0.0111 |
| Shares Short | 56,743 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 102,676 |
| Short Name | MetaVia Inc. |
| Short Percent Of Float | 0.0171 |
| Short Ratio | 0.35 |
| Source Interval | 15 |
| State | MA |
| Symbol | MTVA |
| Target High Price | 30.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 19.33333 |
| Target Median Price | 20.0 |
| Total Cash | 10,310,000 |
| Total Cash Per Share | 2.025 |
| Total Debt | 210,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -7.35 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.417545 |
| Two Hundred Day Average Change | -4.897545 |
| Two Hundred Day Average Change Percent | -0.7631493 |
| Type Disp | Equity |
| Volume | 105,015 |
| Website | https://www.metaviatx.com |
| Zip | 2,138 |